RXI Pharmaceuticals has appointed Jeannette Graf, M.D., and Leroy Young, M.D., to its scientific advisory board.
Westborough, Mass. - RXI Pharmaceuticals has appointed Jeannette Graf, M.D., and Leroy Young, M.D., to its scientific advisory board.
Dr. Graf is a board-certified clinical and research dermatologist with a private practice in Great Neck, N.Y. She is an assistant clinical professor of dermatology at the Mount Sinai School of Medicine and the author of Stop Aging, Start Living.
Dr. Young is the director of the BodyAesthetic Research Center in St. Louis. He is board certified in general surgery and plastic surgery and has held several academic positions in the fields of surgery and plastic surgery at the Washington University School of Medicine in St. Louis.
Currently in phase 1 clinical study, RXI-109 is RXi Pharmaceuticals’ self-delivering RNAi compound (sd-rxRNA) developed to reduce dermal scarring in planned surgeries. Drs. Graf and Young will offer their expertise in in the fields of dermatology and surgery during the continued research and development of the compound, according to company reports.
“Dr. Graf and Dr. Young are notable additions to our Scientific Advisory Board,” Geert Cauwenbergh, Dr. Med. Sci., president and CEO of RXi Pharmaceuticals, says. “Together, Dr. Young and Dr. Graf bring a wide spectrum of scientific and clinical experience to the development effort that RXi has under way with RXI-109, the first self-delivering RNAi to enter into clinical development. In addition, they also bring a unique understanding of the cosmetic surgery and dermatology space, with in-depth knowledge of the need gaps that still exist today in the management of scarring.”